Gan & Lee Pharmaceuticals (603087.SH) has announced that its subsidiary, Gan & Lee Brazil Trading and Pharmaceutical Import Limited Liability Company, recently obtained a Good Manufacturing Practice (GMP) certification issued by the Brazilian Health Regulatory Agency (ANVISA). The certification covers the active pharmaceutical ingredients for insulin aspart and insulin lispro. This successful GMP approval establishes a solid foundation for the company's insulin lispro and insulin aspart products to enter the Brazilian market, marking a significant step forward in the company's internationalization strategy.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.
Comments